These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26938274)

  • 21. Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.
    Stefanachi A; Favia AD; Nicolotti O; Leonetti F; Pisani L; Catto M; Zimmer C; Hartmann RW; Carotti A
    J Med Chem; 2011 Mar; 54(6):1613-25. PubMed ID: 21341743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
    Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1.
    Gobbi S; Hu Q; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
    Eur J Med Chem; 2017 Oct; 139():60-67. PubMed ID: 28797884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of the fungicide epoxiconazole by virtual screening and biological assessment as inhibitor of human 11β-hydroxylase and aldosterone synthase.
    Akram M; Patt M; Kaserer T; Temml V; Waratchareeyakul W; Kratschmar DV; Haupenthal J; Hartmann RW; Odermatt A; Schuster D
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105358. PubMed ID: 30965118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets.
    Hakki T; Bernhardt R
    Pharmacol Ther; 2006 Jul; 111(1):27-52. PubMed ID: 16426683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
    Gobbi S; Hu Q; Foschi G; Catanzaro E; Belluti F; Rampa A; Fimognari C; Hartmann RW; Bisi A
    Bioorg Chem; 2019 May; 86():401-409. PubMed ID: 30769265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New CYP17 hydroxylase inhibitors: synthesis, biological evaluation, QSAR, and molecular docking study of new pregnenolone analogs.
    Al-Masoudi NA; Ali DS; Saeed B; Hartmann RW; Engel M; Rashid S; Saeed A
    Arch Pharm (Weinheim); 2014 Dec; 347(12):896-907. PubMed ID: 25251696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imidazopyridyl compounds as aldosterone synthase inhibitors.
    Whitehead BR; Lo MM; Ali A; Park MK; Hoyt SB; Xiong Y; Cai J; Carswell E; Cooke A; MacLean J; Ratcliffe P; Robinson J; Bennett DJ; Clemas JA; Wisniewski T; Struthers M; Cully D; MacNeil DJ
    Bioorg Med Chem Lett; 2017 Jan; 27(2):143-146. PubMed ID: 27979595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
    Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
    J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
    Baston E; Leroux FR
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):31-58. PubMed ID: 18221052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2.
    Sakakibara R; Sasaki W; Onda Y; Yamaguchi M; Ushirogochi H; Hiraga Y; Sato K; Nishio M; Egi Y; Takedomi K; Shimizu H; Ohbora T; Akahoshi F
    J Med Chem; 2018 Jul; 61(13):5594-5608. PubMed ID: 29878770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
    Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
    Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.
    Liu Y; Wu J; Zhou M; Chen W; Li D; Wang Z; Hornsperger B; Aebi JD; Märki HP; Kuhn B; Wang L; Kuglstatter A; Benz J; Müller S; Hochstrasser R; Ottaviani G; Xin J; Kirchner S; Mohr S; Verry P; Riboulet W; Shen HC; Mayweg AV; Amrein K; Tan X
    J Med Chem; 2020 Jul; 63(13):6876-6897. PubMed ID: 32530624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.
    Hoyt SB; Taylor J; London C; Ali A; Ujjainwalla F; Tata J; Struthers M; Cully D; Wisniewski T; Ren N; Bopp C; Sok A; Verras A; McMasters D; Chen Q; Tung E; Tang W; Salituro G; Clemas J; Zhou G; MacNeil D; Duffy R; Xiong Y
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2384-2388. PubMed ID: 28416132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New biaryl-chalcone derivatives of pregnenolone via Suzuki-Miyaura cross-coupling reaction. Synthesis, CYP17 hydroxylase inhibition activity, QSAR, and molecular docking study.
    Al-Masoudi NA; Kadhim RA; Abdul-Rida NA; Saeed BA; Engel M
    Steroids; 2015 Sep; 101():43-50. PubMed ID: 26051784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imidazolylmethylbenzophenones as highly potent aromatase inhibitors.
    Gobbi S; Cavalli A; Negri M; Schewe KE; Belluti F; Piazzi L; Hartmann RW; Recanatini M; Bisi A
    J Med Chem; 2007 Jul; 50(15):3420-2. PubMed ID: 17585752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
    Cerny MA; Csengery A; Schmenk J; Frederick K
    J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors.
    Castellano S; Stefancich G; Ragno R; Schewe K; Santoriello M; Caroli A; Hartmann RW; Sbardella G
    Bioorg Med Chem; 2008 Sep; 16(18):8349-58. PubMed ID: 18782670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1).
    Schroeder RL; Tram P; Liu J; Foroozesh M; Sridhar J
    Expert Opin Ther Pat; 2016; 26(1):139-47. PubMed ID: 26514241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
    Emmerich J; Hu Q; Hanke N; Hartmann RW
    J Med Chem; 2013 Aug; 56(15):6022-32. PubMed ID: 23869452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.